Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
BACGROUND/OBJECTIVES: In this randomized, placebo-controlled, double-blind study, we evaluated the antihypertensive effects of enzymatic hydrolysate from Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and hypertension. SUBJECTS/METHODS: S. clava flesh tissue hydrolysate (SFTH) (n = 34) and placebo (n = 22) were randomly allocated to the study subjects. Each subject ingested two test capsules (500 mg) containing powdered SFTH (SFTH group) or placebo capsules (placebo group) during four weeks. RESULTS: In the SFTH group, systolic and diastolic blood pressure decreased significantly 4 weeks after ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In addition, the SFTH group exhibited a significant decrease in hemoglobin A1c with a tendency toward improvement in homeostasis model assessment of insulin resistance, triglyceride, apolipoprotein B and plasma insulin levels after 4 weeks. No adverse effects were observed in other indexes, including biochemical and hematological parameters in both groups. CONCLUSION: The results of our study suggested that SFTH exerts a regulatory, antihypertensive effect in patients with T2DM and hypertension.
Abstract
BACGROUND/OBJECTIVES: In this randomized, placebo-controlled, double-blind study, we evaluated the antihypertensive effects of enzymatic hydrolysate from Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and hypertension. SUBJECTS/METHODS: S. clava flesh tissue hydrolysate (SFTH) (n = 34) and placebo (n = 22) were randomly allocated to the study subjects. Each subject ingested two test capsules (500 mg) containing powdered SFTH (SFTH group) or placebo capsules (placebo group) during four weeks. RESULTS: In the SFTH group, systolic and diastolic blood pressure decreased significantly 4 weeks after ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In addition, the SFTH group exhibited a significant decrease in hemoglobin A1c with a tendency toward improvement in homeostasis model assessment of insulin resistance, triglyceride, apolipoprotein B and plasma insulin levels after 4 weeks. No adverse effects were observed in other indexes, including biochemical and hematological parameters in both groups. CONCLUSION: The results of our study suggested that SFTH exerts a regulatory, antihypertensive effect in patients with T2DM and hypertension.
참고문헌 (25)
- Alberti KG, "IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition", Lancet, 366, pp.1059~1062 (2005)
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)", JAMA, 285(19), pp.2486~2497 (2001)
- World Health Organization, "Global health risks mortality and burden of disease attributable to selected major risks" (2009), World Health Organization
- Je JY, "Isolation of angiotensin I converting enzyme (ACE) inhibitor from fermented oyster sauce, Crassostrea gigas", Food Chem, 90, pp.809~814 (2005)
- Unger T, "The role of the renin-angiotensin system in the development of cardiovascular disease", Am J Cardiol, 89, pp.3A~9A (2002)
- Lee JK, "Purification and characterization of angiotensin I converting enzyme inhibitory peptides from the rotifer, Brachionus rotundiformis", Bioresour Technol, 100, pp.5255~5259 (2009)
- Lapointe N, "Activation of vascular tissue angiotensinconverting enzyme (ACE) in heart failure. Effects of ACE inhibitors", J Am Coll Cardiol, 39, pp.776~779 (2002)
- Rossi S, "Australian Medicines Handbook 2006", Australian Medicines Handbook, ~ (2006)
- Sidorenkov G, "Safety of ACE inhibitor therapies in patients with chronic kidney disease", Expert Opin Drug Saf, 13, pp.1383~1395 (2014)
- Ko SC, "Nitric oxide-mediated vasorelaxation effects of anti-angiotensin I-converting enzyme (ACE) peptide from Styela clava flesh tissue and its anti-hypertensive effect in spontaneously hypertensive rats", Food Chem, 134, pp.1141~1145 (2012)
- Ko SC, "Purification and characterization of angiotensin I-converting enzyme inhibitory peptide from enzymatic hydrolysates of Styela clava flesh tissue", Process Biochem, 47, pp.34~40 (2012)
- Matthews DR, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- Lee JK, "Antihypertensive effect of novel angiotensin I converting enzyme inhibitory peptide from chum salmon (Oncorhynchus keta) skin in spontaneously hypertensive rats", J Funct Foods, 7, pp.381~389 (2014)
- Ko SC, "Angiotensin I-converting enzyme (ACE) inhibition and nitric oxide (NO)-mediated antihypertensive effect of octaphlorethol A isolated from Ishige sinicola: in vitro molecular mechanism and in vivo SHR model", J Funct Foods, 18, pp.289~299 (2015)
- Ko SC, "Dieckol, a phlorotannin isolated from a brown seaweed, Ecklonia cava, inhibits adipogenesis through AMP-activated protein kinase (AMPK) activation in 3T3-L1preadipocytes", Environ Toxicol Pharmacol, 36, pp.1253~1260 (2013)
- Lee SH, "Efficacy and safety of a dieckol-rich extract (AG-dieckol) of brown algae, Ecklonia cava, in pre-diabetic individuals:a double-blind, randomized, placebo-controlled clinical trial", Food Funct, 6, pp.853~858 (2015)
- Lee SH, "Octaphlorethol A: a potent α-glucosidase inhibitor isolated from Ishige foliacea shows an anti-hyperglycemic effect in mice with streptozotocin-induced diabetes.", Food Funct, 5, pp.2602~2608 (2014)
- 정은실, "미더덕의 부위별 추출물의 항산화 활성", 한국식품영양과학회지, 37(12), pp.1674~1678 (2008), 한국식품영양과학회
- 강나래, "Purification of Antioxidative Peptide from Peptic Hydrolysates of Mideodeok (Styela clava) Flesh Tissue", Food Science and Biotechnology, 22(2), pp.541~547 (2013), 한국식품과학회[DOI]
- Byung-Hee Chung, "Syringaresinol causes vasorelaxation by elevating nitric oxide production through the phosphorylation and dimerization of endothelial nitric oxide synthase", Experimental and Molecular Medicine, 44(3), pp.191~201 (2012), 생화학분자생물학회
- Ondetti MA, "Enzymes of the renin-angiotensin system and their inhibitors", Annu Rev Biochem, 51, pp.283~308 (1982)
- Kamiya A, "Roles of fluid shear stress in physiological regulation of vascular structure and function", Biorheology, 25, pp.271~278 (1988)
- Ko SC, "Antihypertensive peptide purified from Styela clava flesh tissue stimulates glucose uptake through AMP-activated protein kinase (AMPK) activation in skeletal muscle cells", Eur Food Res Technol, 242, pp.163~170 (2016)
- Henriksen EJ, "Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition", J Cell Physiol, 196, pp.171~179 (2003)
- Toda N, "Salt-induced hemodynamic regulation mediated by nitric oxide", J Hypertens, 29, pp.415~424 (2011)
